Jiangsu Hansoh Pharmaceutical Co., Ltd.

Pharma

Lianyungang, Jiangsu, China · Est. 1995 · 8,000 employees

Jiangsu Hansoh Pharmaceutical is a Chinese pharmaceutical company focused on research, development, manufacturing, and commercialization of innovative drugs across multiple therapeutic areas.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

131

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

22 drugs in development

Phase 34

Phase 27

Phase 114

Preclinical2

By Therapeutic Area

top 6

Oncology

1243%

Infectious Disease

27%

Metabolic & Endocrine

14%

Respiratory

14%

Nephrology

14%

Rare Disease

14%

R&D Momentum

79/100

Pipeline Velocity

49/100

Trial Completion Rate

100/100

Pipeline Concentration

30/100

Pipeline Freshness

57/100

Strategic Signals

↗Active in Infectious Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 5, 2026

Completed

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of HS-20118 in Adult Participants

Nov 3, 2026

Recruiting

A Randomized, Controlled, Open-Label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR C797S Mutation After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

Oct 28, 2026

Active, not recruiting

A Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy Participants

Earlier

Sep 29, 2026TrialA Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506

Sep 24, 2026TrialA Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function.

Sep 17, 2026TrialA Randomized, Open-label, Controlled, Multicenter Phase 3 Trial of HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation.

Sep 5, 2026TrialA Phase I/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Sep 1, 2026TrialA Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10504 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC）

2 more events

Aug 21, 2026TrialA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 Tablets After Single and Multiple Oral Doses in Healthy Subjects and Subjects With Mildly Elevated LDL-C

Aug 19, 2026TrialA Phase I Clinical Trial to Evaluate the Effect of Rifampin on the Pharmacokinetics of HS-10504 in Healthy Participants